MicroRNAs relate to early worsening of renal function in patients with acute heart failure

Bruno, N. et al. (2016) MicroRNAs relate to early worsening of renal function in patients with acute heart failure. International Journal of Cardiology, 203, pp. 564-569. (doi:10.1016/j.ijcard.2015.10.217) (PMID:26569364)

Full text not currently available from Enlighten.

Abstract

Background: Deregulation of microRNAs (miRNAs) may be involved in the pathogenesis of heart failure (HF) and renal disease. Our aim is to describe miRNA levels related to early worsening renal function in acute HF patients. Method and results: We studied the association between 12 circulating miRNAs and Worsening Renal Function (WRF; defined as an increase in the serum creatinine level of 0.3 mg per deciliter or more from admission to day 3), absolute change in creatinine and Neutrophil Gelatinase Associated Lipocalin (NGAL) from admission to day 3 in 98 patients hospitalized for acute HF. At baseline, circulating levels of all miRNAs were lower in patients with WRF, with statistically significant decreased levels of miR-199a-3p, miR-423-3p, and miR-let-7i-5p (p-value < 0.05). The increase in creatinine during the first 3 days of hospitalization was significantly associated with lower levels of miR-199a-3p, miR-27a-3p, miR-652-3p, miR-423-5p, and miR-let-7i-5p, while the increase in NGAL was significantly associated with lower levels of miR-18a-5p, miR-106a-5p, miR-223-3p, miR-199a-3p and miR-423-3p. MiR-199a-3p was the strongest predictor of WRF, with an Odds Ratio of 1.48 (1.061–2.065; p-value = 0.021) and a C-index of 0.701. Conclusions: Our results show that the levels of circulating miRNAs at hospital admission for acute HF were consistently lower in patients who developed worsening of renal function. MiR-199a-3p was the best predictor of WRF in these patients.

Item Type:Articles
Additional Information:This study was supported by a Grant from the Dutch Heart Foundation: Approaching Heart Failure By Translational Research Of RNA Mechanisms (ARENA). The PROTECT trial was supported by NovaCardia, a subsidiary of Merck.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Cleland, Professor John
Authors: Bruno, N., ter Maaten, J. M., Ovchinnikova, E. S., Vegter, E. L., Valente, M. A.E., van der Meer, P., de Boer, R. A., van der Harst, P., Schmitter, D., Metra, M., O'Connor, C. M., Ponikowski, P., Teerlink, J. R., Cotter, G., Davison, B., Cleland, J. G.F., Givertz, M. M., Bloomfield, D. M., Dittrich, H. C., Pinto, Y. M., van Veldhuisen, D. J., Hillege, H. L., Berezikov, E., and Voors, A. A.
Subjects:R Medicine > R Medicine (General)
College/School:College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Robertson Centre
Journal Name:International Journal of Cardiology
Publisher:Elsevier
ISSN:0167-5273
Published Online:11 November 2015

University Staff: Request a correction | Enlighten Editors: Update this record